Recruitment of subjects in industry-sponsored multicenter international clinical trials

被引:0
|
作者
Batagello, Rodrigo [1 ]
机构
[1] Pontificia Univ Catolica Parana, Programa Posgrad Bioet, Curitiba, Parana, Brazil
来源
SAUDE E SOCIEDADE | 2018年 / 27卷 / 04期
关键词
Patient Selection; Clinical Trial; Multicenter Study; International Cooperation; Research Subjects;
D O I
10.1590/S0104-12902018180292
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
This study concerns the recruitment of research subjects in industry-sponsored multicentric international clinical trials carried out at a Brazilian public university between January 2010 and December 2016. A set of 63 clinical trial agreements, administrative and regulatory documents was analyzed. The results showed that 75 countries were involved in these international trials, of which 16% were Latin American. Data about the recruitment of research subjects at the local (356 subjects), national (3774 subjects) and international (82,696 subjects) levels were obtained, as well as information on the number of Brazilian research centers involved and the costs of each trial. Phase III trials were the most frequent (77.78% of the cases) and they estimated a total national enrollment between 18 and 80 research subjects per trial (which means between 4.42% and 11.46% of international recruitment). A negative correlation was found between agreements, research resources, recruitment data, and yearly average dollar exchange rate. All the trials adopted competitive recruitment method associated with payment for subject included in the research. This is worrying and shows contradiction between this practice and the recommended national ethical guidelines. The lack of data on recruitment at the national level reveals, in 19% of the cases, a frequent regulatory process failure. It is concluded that the availability of detailed data on recruitment for researches involving human beings is important for the accurate sizing and organization of the efforts to protect research subjects, and that currently this premise is not being appropriately followed.
引用
收藏
页码:1033 / 1043
页数:11
相关论文
共 50 条
  • [11] Viewpoint: Professional integrity in industry-sponsored clinical trials
    Miller, FG
    Brody, H
    [J]. ACADEMIC MEDICINE, 2005, 80 (10) : 899 - 904
  • [12] The importance of transparency in industry-sponsored multicenter clinical studies - In Response
    Gan, Tong J.
    Apfel, Christian C.
    Kovac, Anthony
    Philip, Beverly K.
    Singla, Neil
    Minkowitz, Harold
    Habib, Ashraf S.
    Carides, Alexandra
    Horgan, Kevin J.
    Evans, Judith K.
    Lawson, Francesca C.
    [J]. ANESTHESIA AND ANALGESIA, 2007, 105 (06): : 1861 - 1862
  • [14] Access to data in industry-sponsored trials
    Lundh, Andreas
    Krogsboll, Lasse T.
    Gotzsche, Peter C.
    [J]. LANCET, 2011, 378 (9808): : 1995 - 1996
  • [15] GUIDELINES FOR CLINICAL INVESTIGATOR INVOLVEMENT IN INDUSTRY-SPONSORED CLINICAL-TRIALS
    PANACEK, EA
    LEWIS, RJ
    [J]. ACADEMIC EMERGENCY MEDICINE, 1995, 2 (01) : 43 - 45
  • [16] Ethical assessment of industry-sponsored clinical trials - A case analysis
    Miller, FG
    Shorr, AF
    [J]. CHEST, 2002, 121 (04) : 1337 - 1342
  • [17] Authorship selection in industry-sponsored publications of dermatology clinical trials
    Tauber, M.
    Paul, C.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (06) : 1669 - 1671
  • [18] Better Regulation of Industry-Sponsored Clinical Trials Is Long Overdue
    Wynia, Matthew
    Boren, David
    [J]. JOURNAL OF LAW MEDICINE & ETHICS, 2009, 37 (03): : 410 - +
  • [19] Exclusion of Pregnant Women From Industry-Sponsored Clinical Trials
    Shields, Kristine E.
    Lyerly, Anne Drapkin
    [J]. OBSTETRICS AND GYNECOLOGY, 2013, 122 (05): : 1077 - 1081
  • [20] Removing the cloud from industry-sponsored, multicentered clinical trials
    Kaushansky, K
    [J]. BLOOD, 2001, 98 (07) : 2001 - 2001